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The skin is an important site for immunological reactions (1-3). Cutaneous
infiltration by T lymphocytes is characteristic of a number of disease states and
T lymphocytes have been observed within the epidermal compartment in graft-
vs.-host disease (4), lichen planus (5), and delayed-type hypersensitivity (6). In
addition, a heterogeneous group ofT lymphomas, collectively termed cutaneous
T cell lymphomas, show directed migration to the skin (7, 8). In contrast, cuta-
neous infiltration by B lymphocytes is rare.
Epidermal keratinocytes (EK)' do not typically express MHC class II antigens,
however, in the presence of a cutaneous T cell infiltrate, EK frequently express
high levels of MHC class II HIA-DR antigens (9-15). It is likely that the
enhanced expression of HLA-DR is a result of T lymphocyte-derived cytokines
including IFNy. In vitro experiments have documented that IFN-y induces the
expression of HLA-DR on EK (16); however the functional significance of HLA-
DR expression by EK is not known. EK produce the important immunoregula-
tory cytokine IL-1 (17, 18). In addition to its role in enhancing T cell prolifer-
ation, IL-1 has been reported to be chemotactic for T cells (19). Currently, very
little is known about the molecular basis ofepidermal T cell interactions and the
consequences of those interactions.
Lymphocyte adhesion to a wide array of cells of hematopoietic and nonhe-
matopoietic origin is required for the induction and maintenance of immune
responses and for effector functions of lymphocytes (20). Interactions of lym-
phocytes with many cell types are inhibited by lymphocyte function-associated
antigen 1 (LFA-1) (CD11a,CD18) mAb (21-25), and consistent with the impor-
tance of adhesion for immune function, several in vitro assays of immune func-
tion are blocked by LFA-1 mAb (26). In the epidermis, T lymphocytes are
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known to be closely apposed to basal EK and Langerhans' cells (4-6, 27), and
intercellular adhesion may be important in maintaining this proximity.
We have described a cell surface glycoprotein, intercellular adhesion molecule
1 (ICAM-1), that is involved in LFA-1-dependent adhesion of lymphocytes (28) .
ICAM-1 expression on dermal fibroblasts and umbilical vein endothelial cells is
increased by IFN-y, IL-1, TNF, lymphotoxin, and LPS (24, 29). Staining of tis-
sue sections has shown that the expression of ICAM-1 on epithelial cells is
restricted to thymic epithelial cells and some kidney tubule epithelial cells. Addi-
tionally, staining of mucosal epithelial cells and EK was seen at sites of immune
responses (24) . This is very similar to the staining pattern of HLA-DR on epi-
thelial cells, suggesting that ICAM-1 and HLA-DR expression on EK and other
epithelial cells might be under common regulation. Since ICAM-1 is involved in
adhesive interactions of T lymphocytes, the coexpression of ICAM-1 and MHC
class 11 antigens on EK could be important for cutaneous immune responses.
Therefore, we have examined the interaction of allogeneic and autologous T
lymphoblasts with cultured EK treated with a variety of cytokines and the rela-
tionship between ICAM-1 expression and lymphocyte adhesion. The role of
ICAM-1 in adhesion has been studied with mAb blockade and reconstitution of
purified epithelioid cell ICAM-1 in planar membranes. Our findings suggest that
ICAM-1 is the primary EK surface molecule that regulates adhesion to T
lymphoblasts.
Materials and Methods
Materials.
￿
rIFN-y expressed in CHO cells with a sp act of 108 U/mg was a gift of
Drs. Daniella Novick or Dina Fisher (Weizmann Institute of Science, Rehovot, Israel);
rIFN-y expressed in Escherichia coli with a sp act of 5 X 107 U/mg was purchased from
Collaborative Research, Lexington, MA). Human rTNF with a specific activity of 108 U/
mg was from Genentech (South San Francisco, CA). Human rIL-1-,Q with a sp act of 2
X 107 U/mg was a gift of Dr. Charles A. Dinarello (Tufts University, Boston, MA). Cell
culture reagents and other reagents were purchased from Sigma Chemical Co. (St. Louis,
MO), with the exception of epidermal growth factor from Collaborative Research, chol-
era toxin from Schwarz-Mann/ICN (Irvine, CA) and hydrocortisone from Calbiochem-
Behring Corp . (San Diego, CA). Protein A-Sepharose CL-4B and Sepharose CL-4B were
purchased from Pharmacia Fine Chemicals (Piscataway, NJ). Iodogen was purchased
from Pierce Chemical Co. (Rockford, IL). FITC-goat anti-mouse IgG was purchased
from Zymed Laboratories (San Francisco, CA). Carrier-free Na...I and Na2S'CrO4 were
purchased from New England Nuclear (Boston, MA).
Monoclonal Antibodies.
￿
RR1/1 (anti-ICAM-1 IgGI) (28), TS1/22 (anti-LFA-la IgGI),
TS1/18 (anti-LFA-1, Mac-1, p150,95 a IgGI), TSI/16 and TS1/2 (anti-HLA DR frame-
work IgGI), TS2/18 (anti-CD2 IgGI), TS2/9 (anti-LFA-3 IgGI) (30), LM2/1 (anti-Mac-
1 a IgGI), SHCL3 (anti-p150,95a IgGl) (31), P3X63Ag8 (nonbinding myeloma IgGl)
(32), and W6/32 (anti-HLA-A,B IgG2a) (33) were used as protein A affinity-purified IgG
or as dilutions of culture supernatants. Anti-Leu-2a(anti-CD8 IgGI), anti-Leu-3a(anti-
CD4 IgGI), and L243 (anti-HLA-DR IgG2a) ascites were obtained from Becton Dickin-
son & Co. (Mountain View, CA). OKT3 (anti-CD3 IgG2a) was obtained from Ortho Phar-
maceutical (Raritan, NJ). A polyclonal rabbit antisera reacting primarily with the VLA-/3
subunit was a gift of Dr. Martin Hemler, Dana Farber Cancer Institute, Boston, MA (34).
Cell Culture.
￿
Con A T lymphoblasts were prepared from PBMC by culturing mono-
nuclear cells in RPMI 1640, 20% FCS, 2 jug/ml Con A for 3 d followed by washing once
and culturing with 1 ng/ml IL-2 for 4-10 d before use. The B lymphoblastoid cell line
JY was maintained in RPMI 1640, 10% FCS (complete medium) . EK were isolated fromDUSTIN ET AL.
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neonatal foreskins or adult skin biopsies and cultured with mouse 3T3 feeder cells in
supplemented DME as previously described (35).
RIA for ICAM-1 Expression.
￿
Purified RR1/1 was iodinated using iodogen to a specific
activity of either 10 or 1 gCi/,ug (24, 36). EK were seeded into 96-well plates at high
density. The cells were allowed to grow to between 60 and 90% confluence. Cells were
then treated as indicated and washed with HBSS 1 mM EDTA to remove dead cells and
any residual feeder cells (RR1/1 does not react with 3T3 cells) and once with complete
medium with 25 mM Hepes at 4°C. An amount of iodinated RR1/1 + cold RR1/1 was
added to each well such that a linear signal was obtained over a range of three orders of
magnitude including the range of ICAM-1 expression obtained on EK (sp act, < 2 ACi/
Ag, with 20 ng/well). Nonspecific binding was determined in the presence of a 100-fold
excess of cold RR1/1 . After 30 min at 4°C, the wells were washed three times and the
bound radioactivity was measured after solubilization with 0.1 N NaOH. Sites/cell were
calculated using a mol wt of 150,000 for IgG.
Immunofuorescence Flow Cytometry. T lymphoblasts were washed three times with
HBSS/10% FCS, 1mM EDTA, 0.025% NaNs. This buffer was used in all subsequent
steps. 106 cells were incubated with specific mAb or P3X63.Ag8 IgG1 at a 1 :1 dilution
of hybridoma culture supernatant for 30 min at 4°C and then washed three times. The
cells were then incubated with FITC-goat anti-mouse IgG at 100 jug/ml (50 111) for 30
min and washed three times. The stained cells were fixed with 1% paraformaldehyde and
stored up to 1 wk at 4°C before analysis on a flow cytometer (Epics V; Coulter Electron-
ics Inc ., Hialeah, Fl or Ortho Diagnostic Systems Inc., Westmead, MA).
Cell Binding Assay.
￿
EK were grown in 96-well plates exactly as for the RIA. T lym-
phoblasts or other cells were labeled with Na5'Cr04 by incubating 4 X 106 cells with 200
uCi of Na5'Cr04 in 1 .2 ml of complete medium/isotonic saline (4 :1) for 1 .5 h at 37°C.
Cells were then washed four times with complete medium. T lymphoblasts were also
washed twice with 5 mM methyl-a-D-mannopyranoside after labeling to remove any resid-
ual surface Con A. Cells (0.5-1 X 105) were added and the plate was incubated at 37°C
for 1 h. The wells were washed four times with 37°C medium (23, 24). All points were
determined in quadruplicate. mAbs were addedjust before the labeled cells, or cells were
pretreated with the relevant mAb and then washed three times before labeled cells
were added.
Immunoprecipitation and SDS-PAGE Analysis.
￿
Purified RR1/1 mAb was coupled to
CNBr-activated Sepharose CL-4B using the procedure of March et al. (37). EK incubated
for 24 h without or with 100 U/ml IFN--y or JY cells were lysed in 25 mM Tris, pH 8.0,
150 mM NaCl, 0.025% NaNs (TSA), 1% Triton X-100, 1 mM PMSF, 5 mM iodoacet-
amide, 200 mTIU (Trypsin inhibitor units)/ml aprotinin (lysis buffer) for 30 min at 4°C
at 5 X 107 cells/ml. Nuclei and other insoluble material were removed by centrifugation
at 12,000 g for 15 min. The lysate was incubated overnight, with 20 A1/ml mouse IgG
Sepharose (prepared as for RR1/1), centrifuged to remove nonspecifically bound com-
ponents, and then ICAM-1 was immunoprecipitated with 20 ,,1/ml RR1/1 Sepharose for
6 h at 4°C. The precipitate was washed thrice with TSA, 1 % Triton X-100, 1 % deoxy-
cholate, 0.1% SDS (38), and finally with TSA and then 50 mM Tris, pH 6.8. The Sephar-
ose was boiled with Laemmli sample buffer containing 50 mM iodoacetamine (nonre-
ducing) and subjected to 8% SDS-PAGE (39). Proteins were visualized using the silver
staining (40) .
Purification of ICAM-1 from HeLa Cells.
￿
ICAM-1 was purified from 2-3 g of HeLa
cells (2-3 X 10) after solubilization in lysis buffer at 5 X 107 cells/ml using the pro-
cedure of Marlin and Springer (41). The lysate was passed over a 1-ml RR1/1-Sepharose
column (1 .5 mg/ml) at a flow rate of 1 ml/min. The column was washed with 10 vol of
TSA, 1% Triton X-100, with 5 vol of 25 mM triethylamine, pH 11, 0 .15 M NaCl, 0 .1%
Triton X-100, and finally with 5 vol of 20 mM sodium phosphate, pH 7.2, 0.15 M NaCl
(PBS), 1% octyl-,#-D-glucopyranoside (OG) (41) . ICAM-1 was eluted in 50 mM triethylam-
ine, pH 12.4, 0 .15 M NaCl, 1 % OG and collected into tubes containing 0.1 vol of 1 M
Tris, pH 7.5, 1 % OG.
Reconstitution of ICAM-1 into Liposomes and Preparation of Planar Mem-1326
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branes. Liposomes were prepared by addition of phospholipid and cholesterol (7 :2
molar ratio) and removal of detergent by dialysis (42, 43). The final protein/lipid ratio
was between 1 :500 and 1 :5,000, and the lipid concentration was 0.1 mM. Planar mem-
branes were prepared as described by Brian and McConnell (44) with several modifica-
tions. Cleaned coverslips (5 mm, Bellco Glass, Inc., Vineland, NJ) were placed in the
bottom of 96-well plate wells, and 30 Eel of liposome suspension was added to each well.
The plate was covered with a damp paper towel to retard evaporation and left for 1 h
at room temperature. The wells were washed five times with HBSS and twice with com-
plete medium, always leaving ^"40 ul in the well to keep the membrane submerged; expo-
sure to air results in instantaneous destruction of the membrane. Cell binding in this
system was done exactly as described for binding of
51 Cr-labeled T lymphoblasts to cell
layers except that the planar membrane was never exposed to an air/water interface.
Results
ICAM-1 Expression on EK
￿
ICAM-1 expression on cultured EK under basal
conditions or after incubation for 24 h with rIFN-y, rIFN-a, rTNF, and rIL-1-
(3 alone or in combinations was quantified using saturating concentrations of
1251-ICAM-1 mAb (Table I). The basal ICAM-1 expression varied between exper-
iments even on the same line from 0 to 50,000 ICAM-1 mAb binding sites/cell.
The basis of the variation has not been systematically studied but small variations
are also observed on fibroblasts (24). Both rIFN-y and rTNF greatly increased
ICAM-1 expression at 24 h. rIFN-y at 1,000 U/ml increased ICAM-1 25-fold
(range, 12.7-33). rTNF had a moderate effect, increasing ICAM-1 expression
about eightfold (range, 2-10) . rIFN-,8 (1,000 U/ml), rIL-1-,B (10 ng/ml), and
LPS (10 pg/ml) (not shown) had no effect on ICAM-1 expression on EK. In
combinations, 1,000 U/ml rIFN-y and 10 ng/ml rTNF were greater than addi-
tive in effect, increasing ICAM-1 expression 49-fold (range, 20-64). Although
rIL-1-# had little effect by itself, it was weakly synergistic with IFN-y, increasing
ICAM-1 expression 32-fold. Cross titration between rIFN-y and rTNF showed
TABLE I
ICAM-I Site Number Analysis on EK
EK in 96-well plates were treated for 24 h with the indicated mediators
and sites/cell was determined with ICAM-1 mAb labeled with 1251 to low
specific activity. All points were determined in triplicate and cells/well
were determined after removal by trypsinization.
Treatment (24 h) Sites/cell Fold increase
X 10-3
None 35 -
rIFN-'y (1,000 U/ml) 940 25
rTNF (10 ng/ml) 296 8
rIL-1-fl (10 ng/ml) 50 1.3
rIFN-/3 (10,000 U/ml) 25 0.7
TNT + IFN-'y 1,800 49
TNT + IL-1-l; 281 7.5
TNF + IFN-0 254 6.9
IFN-7 + IL-1-0 1,200 32
IFN-,y + IFN-a, 940 25
IL-1-0 + IFN-0 86 2.3DUSTIN ET AL.
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FIGURE 1. (a) Synergism between rIFN-y and rTNF
for upregulation of ICAM-1 . EK were grown to 80%
confluence in 96-well plates and treated with the indi-
cated combination rIFN-y and/or rTNF for 24 h. An
RIA was then done on washed monolayers as in meth-
ods.TNF concentrations: 0 (O), 0.1 (0), 1.0 ("), and 10
ng/ml (W. (b) Time course of rIFN-y and rIFN-y/rTNF
effect on ICAM-1 expression. EK were treated for indi-
cated time with 500 U/ml rIFN-y (0)) or 500 U/ml
rIFN-y + 5 ng/ml rTNF (01). The monolayers were
washed and an RIA done as in Materials and Methods.
moderate synergism at high TNF concentrations (Fig. 1 a). ICAM-1 was signifi-
cantly increased by rIFN-y at 1 U/ml with a half-maximal increase occurring at
^-20 U/ml. Marked synergism between rIFN-y and rTNF was only seen at 1
and 10 ng/ml rTNF; 10 ng/ml was the optimal rTNF concentration for increas-
ing ICAM-1 on dermal fibroblasts and endothelial cells (44a).
The time-course of the rIFN-y effect on EK ICAM-1 expression was deter-
mined out to 24 h (Fig. 1 b). An increase in ICAM-1 expression was not detect-
able at 2 h, but became apparent at 4 h for EK treated with rIFN-y or rIFN-y
and rTNF. This is similar to the time course of the rIFN-y effect on dermal
fibroblast ICAM-1 expression (24).
Adhesion of T Lymphoblasts to Epidermal Keratinocytes.
￿
Adhesion of T lympho-
blasts to epidermal cell monolayers was assayed using "Cr-labeled lymphocytes
(Table II). T lymphoblasts were used as a model for large activated lymphocytes
that are known to extravasate most readily during local immune responses, espe-
cially early on (45), and may be more likely to invade the epidermis. When pre-
viously examined, intraepidermal T lymphocytes were found to express HLA-
DR, suggesting that they were activated (5, 14). Adhesion of T lymphoblasts to
untreated epidermal monolayers was minimal and was not affected by mAbs spe-
cific for ICAM-1, LFA-1, CD2, or LFA-3. When epidermal cells were treated
for 24 h with 500 U/ml IFN-y, the adhesion of T lymphoblasts was dramatically
increased from 2.4 to 42%. Adhesion of T lymphoblasts to IFN-y-treated EK
was inhibited to the level seen for untreated EK monolayers by mAb to ICAM-
1 or LFA-1 (Table II). Other mAbs were tested that were previously shown to
block adhesion of HLA-DR-specific cytolytic T lymphocytes to lymphoid target
cells; mAb to HLA-DR, CD2, and LFA-3 were found to have no effect in this
system. The experiments shown were done after a 24-h treatment of EK with
IFN-y, when ICAM-1 is strongly induced but HLA-DR is only weakly or not
expressed (Singer, K., and D. Tuck, unpublished observation) . Identical results1328 T LYMPHOBLAST ADHESION TO EPIDERMAL KERATINOCYTES
TABLE II
LFA-1+ and LFA-1- T Lymphoblast Binding to EK
EK (80% confluent) were treated with medium or with 500 U/ml IFN-y
for 24 h. T lymphoblasts from a normal donor and from a severely
affected LADpatient were "Crlabeled andmonolayerbindingwas mea-
sured. mAbs were addedat between5 and 25 jig/ml. Results arepercent
binding ± SD of quadruplicates.
* Significantly different than IgGcontrol for same treatment category.
were obtained after 48- and 72-h treatment of EK with IFN-f when both ICAM-
1 and HLA-DR are strongly expressed (not shown). T lymphoblasts prepared
from PBMC of a patient with a severe deficiency in the LFA-1, Mac-1, p150,95
family of adhesion glycoproteins (46) were also tested for their ability to bind to
EK (Table II). LFA-1- T lymphoblasts were deficient in binding to IFN-'Y
treated EK, confirming the mAb-blocking results. Since the population of nor-
mal T lymphoblasts prepared by stimulating with Con A contains cells weakly
positive for Mac-1 and p150,95 by immunofluorescence flow cytometry, the
ability of anti-a chain mAbs specific for these antigens was tested. Neither of
these mAbs inhibited adhesion of normal T lymphoblasts to treated EK (Table
II).
In some adhesion experiments, subconfluent monolayers were used to avoid
differentiation of EK, which occurs to a greater extent in confluent cultures.
Adhesion to subconfluent EK monolayers was increased by IFN-'Y treatment of
EK (Fig. 2, compare b and a) and this adhesion to EK was blocked by anti-ICAM-
1 and anti-LFA-1 mAb (Fig. 2, c and d). However, with subconfluent EK we
observed adhesion of T lymphoblasts to the spaces between EK colonies (Fig. 2
d) . This substratum adhesion was not inhibited by anti-ICAM-1 (not shown) or
anti-LFA-1 mAb (Fig. 2 d). This binding was responsible for the background of
1-2% anti-ICAM-1-resistant adhesion seen in more confluent untreated and
IFN-'Y-treated EK (Table II), as shown by inspection of washed monolayers .
Adhesion of T lymphoblasts to plastic was not seen in binding to subconfluent
dermal fibroblasts (24), suggesting that the plastic binding was dependent on the
presence of EK and possibly the result of binding to an extracellular matrix
component secreted by EK. A polyclonal rabbit antiserum to the VLA family of
surface proteins, which includes the human fibronectin receptor and two poten-
mAb
EK:
Normal
untreated
T cells
donor
IFN-y
bound
Untreated
LADdonor
IFN-y
% ± SD
IgG1 control 2.4 ± 0.5 42 ± 1.8 1.4 ± 0.7 1.8 ± `.).9
Anti-ICAM-1 2.3 ± 0.7 2.4 ± 1.0* 0.8 ± 0.7 1.7 ± 1.0
Anti-LFA-1 2.1 ± 0.8 2.1 ± 4.1* - 2.0 ± 0.4
Anti-Mac-1 - 40 ± 3.0 - -
Anti-p150,95 - 43 ± 2.1 - -
Anti-HLA-DR - 44 ± 1.2 0.9 ± 0.3 1.9 ± 0.6
Anti-CD2 - 40 ± 1.8 1.5 ± 0.9 2.0 ± 0.8
Anti-LFA-3 - 41 ± 2.0 2.1 ± 0.4 1.4 ± 1.0DUSTIN ET AL.  1329 
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FIGURE 3. Dose-response for IFN-'y effect on T lym-
phoblast adhesion to EK. EK were grownto 90% conflu-
ence in 96-well plates and treated with the indicated
concentration of rIFN-y for 24 h. The monolayers were
extensively washed and"Cr-labeled Tlymphoblasts were
added and incubated with cells for I h at 37°C in the
presence of the indicated mAb. Unbound cells were
washed out and the percent bound cells determined.
tial receptors found on T lymphoblasts (34), did not block this adhesion sug-
gesting that this adhesion is not mediated by a member of this family (not
shown).
Dose-dependent Effect of IFN-y on Lymphocyte Adhesion. The relationship
between adhesion and ICAM-1 density was further examined by measuring
adhesion of T lymphoblasts to EK monolayers treated with increasing concen-
trations of IFN-y (Fig. 3). The IFN-y dose responses for ICAM-1 upregulation
and T lymphoblast adhesion were very similar (compare Figs. 1 a and 3). The
mAb blocking pattern was the same over the entire range of IFN-y concentra-
tions; anti-ICAM-1 and anti-LFA-1 inhibited strongly and anti-HLA-DR had no
effect.
Binding of T Lymphocytes to Autologous and Allogeneic EX
￿
While antibodies to
HLA-DR and HLA-A,B (not shown) did not block the adhesion of T lympho-
blasts to IFN-y-stimulated EK, it remained a possibility that the adhesion might
be enhanced by alloreactivity of T lymphoblasts toward the EK. Therefore, bind-
ing experiments were done using syngeneic combinations of T lymphoblasts and
EK (forearm biopsy) in parallel with allogeneic combinations (Table III). No sig-
nificant difference was seen between the binding of T lymphoblast line A to EK
line A or B, and this binding was similar to the binding of T lymphoblast line C
to either EK A or B in both efficiency and inhibition by anti-ICAM-1 and anti-
LFA-1 mAb (Table III). No inhibition of syngeneic adhesion was seen with anti-
HLA-DR.
Biochemical Characterization of IFN-y-Induced ICAM-1 from EK. ICAM-1
immunoprecipitated from IFN-y-treated EK had a mean Mr of 100,000 with a
range from 88,000 to 113,000 . ICAM-1 immunoprecipitated from the same
number of untreated EK could not be detected (Fig. 4, lanes 2 and 4). A higher
quantity of HLA-A,B was also seen with IFN-y treatment (Fig. 4, lanes 3 and
5). ICAM-1 immunoprecipitated from JY cells in parallel has a slightly lower M,
of 92,000 (Fig. 4, lane 6).
Binding of T Lymphoblasts to ICAM-1 in Planar Membranes.
￿
It has been dem-
onstrated (25) that ICAM-1 from a B lymphoblastoid cell line has ligand activity
for the LFA-1-dependent lymphocyte adhesion pathway. To extend this result
to ICAM-1 isolated from an epithelial source, ICAM-1 was immunoaffinity pur-
ified from HeLa cells (Fig. 4, lane 1) and reconstituted into glass-supported
planar lipid membranes. As a control, human glycophorin was also reconstituted
into planar membranes. T lymphoblasts efficiently bound to ICAM-1-bearingDUSTIN ET AL.
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TABLE III
Allogeneic and Syngeneic TLymphoblast/EK Adhesion
T cells bound
EK from twodonors (A, adultforearm; B, foreskin) were grownto 70% confluence in 96-well plates
and treated for24 h with medium (untreated) or 500 U/ml rIFN-.y. T lymphoblasts from donor A
(day 7) and an unrelated donor C (day 8) were labeled with chromium and monolayer adhesion
assays were done. mAbs were present during the adhesion assayat between 5 and 25 Ng/ml.
*Significantly different than IgG control for same treatmentcategory. In the presence of anti-LFA-
1 andanti-ICAM-1, all bindingwas to areas betweencells by visual inspection.
planar membranes but not to glycophorin in planar membranes (Table IV).
When ICAM-1 and glycophorin were mixed in an equimolar ratio before recon-
stitution, T lymphoblast adhesion was as efficient as to ICAM-1 alone. T lym-
phoblasts adhering to ICAM-1 in planar membranes were spread and some cells
were highly elongated (not shown) . This adhesion was blocked completely by
anti-ICAM-1 mAb binding to the planar membrane or anti-LFA-1 mAb binding
to T lymphoblasts (Table IV) . Furthermore, the LFA-1-dependent adhesion was
blocked by EDTA in excess of divalent cations and no adhesion occurred at 4°C.
These results demonstrate that epithelial cell ICAM-1 can mediate T lymphocyte
adhesion in the absence of other epithelial cell membrane components.
Isolation and Characterization of Adherent T Lymphoblasts.
￿
The highest level of
T lymphoblast binding obtained for IFN--y/TNF-treated keratinocytes or ICAM-
1 in planar membranes was 50% (range, 20-50%). This percentage of binding
could represent a stochastic process (i.e., equilibrium between attachment and
detachment) acting on a population of cells with uniform binding capacity, or
heterogeneity within the T lymphoblast population containing cells having dif-
ferent ligand density requirements for stable adhesion. To address this question,
the surface phenotype of adherent T lymphoblasts was determined by immu-
nofluorescence flow cytometry after panning on ICAM-1 in planar membranes
supported by 12-mm glass cover slips or on IFN-y-treated EK monolayers
(Cavander, D. E., D. O. Haskard, D. Maliakkal, and M. Ziff, submitted for pub-
lication). Nonadherent cells were removed by six rinses with warm media and
adherent cells were recovered by addition of HBSS containing 2.5 mM EDTA,
which rapidly released the adherent blasts without damaging membranes or EK
T cell type mAb EK
Untreated
type A
IFN--y
EK
Untreated
type B
IFN--y
%±SD
A IgG control 4.6 ± 1.0 34 ±1.8 8.4 ± 2.0 35 ±2.9
Anti-ICAM-1 3.3 ± 0.8 4.5 ±1.2* 8.1 ± 1.9 9.8 ±1.1*
Anti-LFA-1 1.9 ± 0.7 5.7 ±0.7* 7.6 ± 1.7 12 ±2.2*
Anti-HLA-DR 2.4 ± 0.5 31 ±3.8 9.0 ± 3.1 35 ±3.6
C IgGcontrol 4.8 ± 0.6 29 ±1.4 7.1 ± 2.5 31 ±2.5
Anti-ICAM-1 4.1 ± 0.8 5.0 ±0.3* 6.8 ± 1.6 10 ±1.3*
Anti-LFA-1 4.1 ± 1.5 6.1 ±1.4* 7.0 ± 2.3 11 ±1.7*
Anti-HLA-DR 4.2 ± 1.1 38 ±2.1 8.1 ± 0.9 33 ±0.81332
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FIGURE 4 .
￿
SDS-10%-PAGE of ICAM-1 from
HeLa and EK . HeLa ICAM-1 was purified and
100 ng wasloaded (lane 1) . Keratinocytes were
grown to confluence in 75-cm2 flasks and
treated with medium (lanes 2 and 3) or 1,000
U/ml IFN--y (lanes 4 and 5) . Lysis buffer was
added directly to the flasks and 4 X 107 JY
cells were lysed in parallel . Immunoprecipi-
tates were done using ICAM-I mAb (lanes 2,4,
and 6) or HLA-A,B mAb (lanes 3,5, and 7) on
half of each lysate .
monolayers . Approximately half of the cells visibly adherent to EK monolayers
were not accessable to the EDTA wash, apparently due to their intercalation
between the EK . Aliquots of unseparated cells and adherent cell fractions were
analyzed . Unseparated Con A blasts from several donors were similar in phe-
notype : 100% CD2+, 100% CD3+, 33% CD8+, 65% CD4+, and 20-30% Mac-
1 + (CD11 c) . T lymphoblasts bound to ICAM-1 planar membranes were a sub-51 2
256
512
512
256
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TABLE IV
Binding of TLymphoblasts to HeLa ICAM-I in Glass-Supported Planar Membranes
Binding of normal Tlymphoblasts to ICAM-1 and/or glycophorin-bearing planar membranes was
measured. Data presented as percent cells bound ± SD of quadruplicate determinations.
* Significantly different than value in first row.
population enriched for larger cells by forward-angle light scatter with higher
expression of LFA-1 (2.4-fold) and CD2 (2.1-fold) (Fig. 5). Less enrichment in
linear fluorescence was seen for CD4 (1 .4-fold), CD8 (1 .2-fold), CD3 (1 .1-fold)
and IL-2-R (Tac) (1-fold) expression, showing the enrichment for higher surface
expression was selective for some markers. The enrichment for both LFA-1 and
CD2 cell adhesion glycoproteins is notable since CD2 does not appear to be
directly involved in adhesion to ICAM-1 in planar membranes (not shown and
Dustin, M. L. and T. A. Springer, submitted for publication). The moderate
enrichment for expression of CD8 by ICAM-1 planar membrane-bound CD8+
T lymphoblasts contrasted with the substantial enrichment for CD8+ cells (73%
positive) relative to CD4+ cells (27% positive). Similarly, T lymphoblasts bound
to IFN-y-treated EK monolayers were enriched for larger cells and expressed
FIGURE 5.
￿
Surface phenotype of T lympho-
blasts adherent to ICAM-1 in artificial mem-
branes. Glass-supported planar membranes
with ICAM-1 were made as described in Mate-
rials and Methods on 12-mm coverslips in 24-
well plates. Bound T cells (10% of input) were
recovered and analyzed as in Materials and
relative fluorescence intensity
￿
Methods.
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Pretreatments T cells bound
Tblasts Membrane
Assay Membrane composition
ICAM-1 Glycophorin Both
± SD
None None IgG1 control 26 ±3.1 0.4 ±0.2 25 ± 1.6
None Anti-ICAM-1 IgGI control 0.1 ±0.1* 0.3 ±0.2 -
None Anti-LFA-1 IgGI control 22 ±0.9 0.3 ±0.3 -
Anti-ICAM-1 None IgGI control 28 ±2.6 0.3 ±0.1 -
Anti-LFA-1 None IgGI control 0.3 ±0.02* 0.4 ±0.3 -
None None EDTA 0.2 ±0.3* 0.3 ±0.4 -
None None 4°C 0.1 ±0.1* 0.05 ±0.1 -1334
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higher quantities of several surface markers (not shown). Under conditions
where 25% of input T lymphocytes were bound to EK monolayers, CD2, CD8,
and CD4 showed 1 .1-1 .2-fold higher expression, while LFA-1 showed 1 .5-fold
higher expression. The adherent population was enriched for CD8 + cells (45 vs.
33% positive) and depleted of CD4+ cells (38 vs. 66% positive). The adherent
cells were also enriched for Mac-1 (40 vs. 20% positive) which is expressed on
some CD8+ T lymphocytes and large granular lymphocytes (not shown).
Discussion
We have studied the role of the LFA-1 ligand, ICAM-1, in lymphocyte adhe-
sion to EK. ICAM-1 expression on cultured EK was dramatically upregulated by
treatment of keratinocytes with IFN-y and more weakly upregulated by TNF. T
lymphoblasts failed to adhere to untreated EK monolayers, but were strongly
adherent to IFN-y-treated monolayers. Adherence and ICAM-1 expression
showed similar dependence on IFN-y concentration. mAb-blocking studies
showed that adhesion was dependent on LFA-1 on the T lymphoblast and
ICAM-1 on the EK. Studies on ICAM-1 purified from an epithelioid cell line,
HeLa, and reconstituted in an artificial lipid membrane showed that it is a ligand
for LFA-1.
Comparison of results on EK cells to studies on dermal fibroblasts and endo-
thelial cells show that the effect of immunomodulatory agents on ICAM-1
expression is highly dependent on cell lineage. Human dermal fibroblast ICAM-
1 is strongly upregulated not only by IFN-y, but also by IL-1, TNF, and LPS.
The latter agents have little or no effect on EK ICAM-1 . On endothelial cells,
the effects of these mediators is reversed with respect to EK. Endothelial cell
ICAM-1 is strongly upregulated by TNF, LPS, and IL-1, and only weakly by
IFN-y (29, 44a). The polarity between endothelial and EK ICAM-1 regulation
by cytokines is intriguing since these cells form the closest and farthest, respec-
tively, tissue boundaries to lymphocytes migrating from the blood. Fibroblasts,
which upregulate ICAM-1 in response to the widest range of mediators and are
intermediate between endothelial cells and EK in sensitivity, are also interme-
diate in their distance from blood lymphocytes. The sensitivity of EK to lympho-
cyte-activation products, as opposed to the greater sensitivity of endothelial cells
to monocyte and bacterial products, may influence the nature of the inflam-
matory response to these stimuli. These results are consistent with parallel
observations that ICAM-1 is induced on EK in vivo in delayed-type hypersensi-
tivity responses, but not in croton oil-induced inflammation; both cases are
accompanied by mononuclear cell infiltrates, but activation of T lymphocytes
would only occur in the delayed-type hypersensitivity reaction (Wantzin, G. L.,
E. Ralfkiaer, C. Avnstorp, M. Czajkowski, S. D. Marlin, and R. Rothlein, manu-
script in preparation).
While ICAM-1 appears to be critical for lymphocyte adhesion to EK, ICAM-
1 expression cannot clearly explain the initial invasion of the epidermis by T
lymphocytes or T lymphoma cells since the EK ICAM-1 is separated from extrav-
asated T lymphocytes in the dermis by a highly organized and continuous extra-
cellular matrix, the basement membrane. It is interesting that T lymphoblastsDUSTIN ET AL.
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adhere to surfaces on which EK have been cultured. This adhesion was not
blocked by anti-LFA-1 mAb. These receptors also appear to be distinct from the
VLA family of heterodimers since a function blocking rabbit antisera to the
common /3 subunit of these molecules did not inhibit adhesion to the EK matrix.
These observations suggest that T lymphocytes may express uncharacterized
receptors for EK basement membrane components.
The interaction between LFA-1 and ICAM-1 was the only detectable pathway
of T lymphoblast adhesion to EK. In other experimental systems, additional
LFA-1-dependent, ICAM-1-independent as well as LFA-1-independent pathways
have been found. ICAM-1 mAbs do not inhibit phorbol ester-stimulated homo-
typic aggregation of the SKW3 T lymphoma cell line which is inhibited by LFA-
1 mAbs (28), suggesting the existence of LFA-1 ligands distinct from ICAM-l .
Similarly, cytolytic T lymphocyte adhesion to some target cells is inhibited by
LFA-1 mAbs, but not ICAM-1 mAbs, while ICAM-1 mAb is a potent inhibitor
of cytolytic T lymphocyte adhesion to and killing of, for example, the U937 his-
tiocytic leukemia cell line (47). Adhesion of T lymphocytes to cultured endothe-
lial cells involves at least three pathways based on functional experiments with
LFA-1 and ICAM-1 mAb (44a); one is LFA-1 and ICAM-1 dependent, the sec-
ond is LFA-1 dependent and ICAM-1 independent, and a third is LFA-1 inde-
pendent. While endothelial cells express at least two LFA-1 ligands, only the
ICAM-1 dependent pathway is upregulated (44a) by cytokines or LPS. There-
fore, EK appear to express only a single pathway in contrast to dermal fibro-
blasts and endothelial cells with at least two and three pathways respectively.
In addition to adhesion mediated by LFA-1 and ICAM-1, another pathway for
T lymphocyte adhesion is mediated by the interaction of CD2 and LFA-3 (20).
This pathway was initially defined for interaction of cytolytic T lymphocytes with
target cells but subsequently has been shown to mediate interaction of thymo-
cytes and thymic epithelial cells (48) . Unlike thymic epithelial cells, EK did not
adhere to thymocytes by the CD2/LFA-3 pathway although EK do express LFA-
3 (48). Therefore, ICAM-1 appears to be the only adhesion pathway used in
lymphocyte-EK binding.
ICAM-1 purified from B lymphoblastoid cells (41), endothelial cells (44a), and
epithelial cells mediates efficient, LFA-1-dependent lymphocyte adhesion when
reconstituted into planar membranes. Adhesion to epithelial cell ICAM-1 has all
of the properties of LFA-1-dependent adhesion to other cells including temper-
ature sensitivity and a requirement for divalent cations. Furthermore, T lym-
phoblasts adhering to ICAM-1 from all three sources exhibit spreading, which
is also seen when T lymphoblasts adhere to cell monolayers and is associated
with a high degree of motility and crawling between cells (49). Therefore, LFA-
1/ICAM-1-dependent adhesion may be important for T lymphocyte motility in
the dermis (fibroblast ICAM-1) and the epidermis (EK ICAM-1) when ICAM-1
expression is increased by immunological or other stimuli.
Our results indicate that polyclonal T lymphoblasts display heterogeneity in
their ability to bind IFN-,y-treated EK or ICAM-1 in planar membranes. This
heterogeneity is reflected in the expression of particular antigens that are known
to be involved in cell-to-cell interactions, LFA-1, CD2, CD4, CD8, Mac-1, and
HLA-A,B. Adherent T lymphoblasts were enriched for cells expressing high lev-1336
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els of these antigens, particularly LFA-1 and CD2, while expression of CD3 and
CD25 epitopes was similar between the adherent and initial populations. The
adherent subpopulation was enriched for cells expressing CD8, but contained a
significant number of CD4+ cells. An attractive hypothesis is that cells with
higher LFA-1 density are more adherent to surfaces expressing LFA-1 ligands
and that some other markers are coordinately expressed, although the state of
lymphocyte activation may also be important (50, 51). Coordinated expression
of LFA-1, CD2, and LFA-3 has been shown on resting peripheral blood T lym-
phocytes; and lymphocytes with immunological memory have been distinguished
from naive lymphocytes by expression of LFA-3 and by higher expression of
LFA-1 and CD2 (52).
It has been suggested that MHC class II antigen expression by EK may have
a significant immunological role in allograft rejection (4, 10, 11). While expres-
sion of MHC class II antigens may enable EK to present antigens to helper T
lymphocytes they do not appear to be required for adhesion of polyclonal T
lymphoblasts to IFN-y-stimulated EK in allogeneic or syngeneic systems. How-
ever, the cooexpression of ICAM-1 and HLA-DR could facilitate adhesion and
subsequent MHC class II antigen-restricted antigen presentation to T lympho-
cytes. The role of LFA-1/ICAM-1 interaction in immunological function of IFN-
y-treated normal EK and other epithelial cell types requires further study in
light of the finding that IFN-y increases expression of ICAM-1 on EK. EK may
require prior exposure to IFN-y to act as efficient targets for cytolytic T lym-
phocytes or as APC.
Summary
The cell surface expression and function of the LFA-1 ligand, intercellular
adhesion molecule 1 (ICAM-1), on epidermal keratinocytes (EK) was studied.
ICAM-1 expression on the surface of cultured EK was either absent or weak,
but was induced by treating EK with rIFN-y or TNF for 4-48 h. IFN-y and
TNF were synergistic. IFN-y treatment increased T lymphoblast adhesion from
< 2% to 20-40%, with a concentration dependence similar to that seen for
ICAM-1 induction . All of the adhesion to EK was inhibited by LFA-1 and
ICAM-1 mAbs, but not by HLA-DR, CD2, or LFA-3 mAbs. There was no dif-
ference in the level of T lymphoblast adhesion to IFN-y-treated allogeneic or
autologous EK. ICAM-1 purified from the HeLa epithelioid cell line and recon-
stituted into planar membranes also supported efficient adhesion of T lympho-
blasts that was blocked by LFA-1 mAb bound to the T lymphoblasts or ICAM-
1 mAb bound to the planar membranes. T lymphoblasts adherent to EK or
ICAM-1 planar membranes were isolated by panning, and surface markers were
analyzed by immunofluorescence flow cytometry. The adherent T cells were a
phenotypically skewed subpopulation. They were enriched for CD8+ cells and
expressed 1 .5-2 .5-fold higher LFA-1 and CD2 compared with the unseparated
population.
We thank Dr. Druie Cavander for sharing prepublication results that stimulated the
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Note added in proof Nickoloff et al. (53) have recently reported that IFN-7 treatment
of cultured keratinocytes enhances their binding of lymphocytes.
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